Sofinnova Partners Raises Another $750M to Back Biotech, Medtech Startups

Sofinnova Partners raises another $750M to back biotech, medtech startups

The new fund will mostly support biotechs making new drugs, with investments spanning from initial financings to follow-on rounds.

Sofinnova Partners closes €650M ($750M) Capital XI, greatly exceeding initial target to back early-stage healthcare deals

Total capital raised across Sofinnova’s platform reaches €1.5Bn over the past year Sofinnova Capital XI is actively investing in early-stage biotech and medtech companies across Europe and the US PARIS, France – November 17, 2025 – Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the close of […] The post Sofinnova Partners closes €650M ($750M) Capital XI, …

Sofinnova secures $750M for 11th fund focused on drugmakers nearing the clinic

Paris-based VC firm Sofinnova Partners has collected €650 million ($750 million) for the latest iteration of a flagship fund focused on preclinical life science investments, known as Capital XI. Just like Sofinnova’s previous Capital funds ...

Sofinnova Partners Launches $750 Million Fund to Support Biotech and Medtech Startups

Sofinnova Partners has secured $750 million in a new fu […] The post Sofinnova Partners Launches $750 Million Fund to Support Biotech and Medtech Startups first appeared on GeneOnline News. The post Sofinnova Partners Launches $750 Million Fund to Support Biotech and Medtech Startups appeared first on GeneOnline News.

Sofinnova Partners surpasses target with €650m fund to back up early-stage biotech - European Biotechnology Magazine

Sofinnova Partners has closed its new investment fund, Capital XI, at €650m, far exceeding its original target. The early-stage biotech and medtech-focused fund will invest mostly in Series A, but also seed financings of companies, including oncology, inflammation and immunology, CNS, and cardio-metabolic diseases. Sofinnova Capital XI closes at €650m to expand early-stage biotech investing, backing seed and Series A companies in Europe and the …